Skip to content

Optimization and application of non-invasive Helicobacter pylori identification and drug resistance multiple genetic detection system

Optimization and application of non-invasive Helicobacter pylori identification and drug resistance multiple genetic detection system

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000037565
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspepsia associated with Helicobacter pylori infection

Interventions

Gold Standard:(1)Reference standard for the identification of Helicobacter pylori (multiple combinations): 1. Helicobacter pylori in vitro culture combined with microscopic examination. 2. C13- Breat
and&#32
Detection&#32
System(non-invasive&#32
Hp-IDMG)

Sponsors

Fudan University Huadong Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients in Huadong Hospitals Gastroenterology Clinic from October 2020 to September 2022 who had dyspeptic symptoms and undergone gastroscopy, gastric mucosal biopsy and 13C-breath test; 2. Any age; 3. The diagnosis of dyspepsia is based on the definition of the gastrointestinal motility group of the Digestive Branch of the Chinese Medical Association in 2007: clinical manifestations are symptoms of pain or burning in the upper abdomen, fullness of the upper abdomen after a meal, and early satiety, which may be accompanied by loss of appetite, belching, and nausea Or vomiting and other symptoms.

Exclusion criteria

Exclusion criteria: 1. Patients with active bleeding confirmed by endoscopy; 2. Patients who have received Hp eradication therapy; 3. Patients who have taken bismuth, proton pump inhibitors, H2 receptor antagonists and antibiotics in the past month; 4. Patients with a history of allergies or a positive skin test during this treatment; 5. Patients during pregnancy and lactation.

Design outcomes

Primary

MeasureTime frame
Helicobacter pylori positive rate;Helicobacter pylori drug resistance rate;

Countries

China

Contacts

Public ContactZhang Yanmei

Fudan University Fenglin Campus

15618653286@163.com+86 15618653286

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026